Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...
Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...
The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...
The U.S. Food and Drug Administration (FDA) has approved Cardamyst™ (etripamil) nasal spray to treat adults with paroxysmal supraventricular tachycardia (PSVT). This rapid-acting, self-administered ...
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...
Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...
Cardiovascular clinicians can bill new or revised codes for PCI, lower extremity revascularization (LER), coronary plaque analysis and other services starting Jan. 1, 2026. The ACC Advocacy team has ...
A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...
The following are key points from the 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency ...
An ACC Concise Clinical Guidance (CCG) report on "Transthyretin Cardiac Amyloidosis Evaluation and Management" provides updated strategies and best practices for clinicians, taking into account ...
The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...
The U.S. Food and Drug Administration has approved on April 2 the Abbott TriClip™, a transcatheter edge-to-edge repair (TEER) system specifically designed for the treatment of tricuspid regurgitation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results